Compare Halliburton Company (HAL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Spyre Therapeutics Inc. Common Stock — how do they compare? Halliburton Company trades at $32.54 (market cap $27.32B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Halliburton Company is far larger — about 3.6× Spyre Therapeutics Inc. Common Stock's market cap, and Halliburton Company pays a 2.07% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HAL | SYRE | |
|---|---|---|
Market Cap | $27.32B | $7.52B |
Volume | 5,347,556 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $42.98 | $108.92 |
52-Week Low | $21.82 | $22.18 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $33.47B | $6.52B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.83, up 0.71% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a P/E of 17.17 and ROE of 14.89%, though 2025 net income declined to $1.28B from $2.5B in 2024. Recent developments include Venezuela energy agreements and a Cyprus deepwater contract win, positioning for international growth amid volatile oil markets.
Wall Street maintains strong bullish sentiment with 73% buy ratings and a $43.11 price target, representing 31% upside. Key risks include oil price volatility and execution challenges in new markets. The stock offers value with reasonable valuation metrics but faces near-term headwinds from declining profitability trends.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
